NASDAQ:BIOR Biora Therapeutics (BIOR) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free BIOR Stock Alerts $0.73 -0.01 (-1.99%) (As of 05/10/2024 08:54 PM ET) Add Compare Share Share Today's Range$0.73▼$0.7650-Day Range$0.60▼$1.3352-Week Range$0.59▼$6.70Volume107,600 shsAverage Volume407,951 shsMarket Capitalization$26.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biora Therapeutics alerts: Email Address Biora Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.46) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.75 out of 5 starsMedical Sector852nd out of 925 stocksPharmaceutical Preparations Industry402nd out of 430 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Biora Therapeutics.Read more about Biora Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.52% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biora Therapeutics has recently increased by 4.29%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOR. Previous Next 2.6 News and Social Media Coverage News SentimentBiora Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for BIOR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.97% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biora Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($1.46) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biora Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Biora Therapeutics Stock (NASDAQ:BIOR)Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Read More BIOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOR Stock News HeadlinesMay 13, 2024 | americanbankingnews.comBiora Therapeutics (BIOR) Set to Announce Earnings on WednesdayMay 8, 2024 | americanbankingnews.comBiora Therapeutics (NASDAQ:BIOR) Trading Down 1.5%May 13, 2024 | Unstoppable Prosperity (Ad)Charles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 7, 2024 | finance.yahoo.comBiora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate UpdateMay 6, 2024 | globenewswire.comBiora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024April 30, 2024 | globenewswire.comBiora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600April 18, 2024 | msn.comBiora Therapeutics (BIOR) Price Target Decreased by 62.95% to 10.51April 15, 2024 | nasdaq.comBiora Therapeutics, Inc. Common Stock (BIOR)May 13, 2024 | Unstoppable Prosperity (Ad)Charles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. April 10, 2024 | stockhouse.comBiora Therapeutics Announces New Patent Covering its BioJet(TM) Liquid Jet Delivery TechnologyApril 9, 2024 | markets.businessinsider.comBiora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery InnovationsApril 8, 2024 | globenewswire.comBiora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery TechnologyApril 4, 2024 | markets.businessinsider.comBiora Therapeutics Gets Positive Interim Data From Clinical Trial Of BT-600 With NaviCap; Stock DownApril 4, 2024 | globenewswire.comBiora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform DevelopmentApril 3, 2024 | globenewswire.comBiora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 2, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60%April 1, 2024 | finance.yahoo.comBiora Therapeutics Full Year 2023 Earnings: Beats ExpectationsApril 1, 2024 | msn.comPrecision Biosciences, Mesoblast, Pulse Biosciences among healthcare moversApril 1, 2024 | marketwatch.comBiora Therapeutics Shares Drop 26% After Pricing of Direct OfferingApril 1, 2024 | globenewswire.comBiora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 28, 2024 | seekingalpha.comBiora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comBIOR: Negotiations AcceleratingMarch 27, 2024 | finance.yahoo.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | benzinga.comBiora Therapeutics: Q4 Earnings InsightsMarch 27, 2024 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 27, 2024 | finance.yahoo.comQ4 2023 Biora Therapeutics Inc Earnings CallMarch 26, 2024 | globenewswire.comBiora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsSee More Headlines Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/12/2024Next Earnings (Confirmed)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOR CUSIPN/A CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees58Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,110,000.00 Net MarginsN/A Pretax Margin-3,110,600.00% Return on EquityN/A Return on Assets-147.40% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.30 Sales & Book Value Annual Sales$4,000.00 Price / Sales6,573.95 Cash FlowN/A Price / Cash FlowN/A Book Value($3.73) per share Price / Book-0.20Miscellaneous Outstanding Shares35,884,000Free Float17,594,000Market Cap$26.30 million OptionableOptionable Beta1.22 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Aditya P. Mohanty M.B.A. (Age 57)CEO & Director Comp: $984.14kMr. Eric d'Esparbes (Age 56)Chief Financial Officer Comp: $748.26kMr. Clarke Neumann J.D. (Age 60)Senior VP, General Counsel & Secretary Comp: $724.62kEric FoxVP of Finance & Accounting & TreasurerMr. Troy Seelye (Age 60)Chief Information Officer Mr. George Gianakopoulos (Age 63)Senior Vice President of Sales Ms. Robyn HattonHead of Human ResourcesMr. Kevin Howe Ph.D.Senior VP of Strategic OperationsDr. Sharat Singh Ph.D. (Age 65)Head of Research Dr. Paul Shabram M.B.A.Head of Technical OperationsMore ExecutivesKey CompetitorsLipocineNASDAQ:LPCNUnity BiotechnologyNASDAQ:UBXForte BiosciencesNASDAQ:FBRXIterum TherapeuticsNASDAQ:ITRMAcasti PharmaNASDAQ:ACSTView All Competitors BIOR Stock Analysis - Frequently Asked Questions Should I buy or sell Biora Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOR shares. View BIOR analyst ratings or view top-rated stocks. How have BIOR shares performed in 2024? Biora Therapeutics' stock was trading at $1.35 at the beginning of 2024. Since then, BIOR stock has decreased by 45.7% and is now trading at $0.7328. View the best growth stocks for 2024 here. When is Biora Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our BIOR earnings forecast. How can I listen to Biora Therapeutics' earnings call? Biora Therapeutics will be holding an earnings conference call on Wednesday, May 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Biora Therapeutics' earnings last quarter? Biora Therapeutics, Inc. (NASDAQ:BIOR) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.03. When did Biora Therapeutics' stock split? Biora Therapeutics's stock reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Biora Therapeutics' major shareholders? Biora Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L and Surbhi Sarna. View institutional ownership trends. How do I buy shares of Biora Therapeutics? Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIOR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
